Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.59 |
| ▸ | ITGAL | P20701 | 20/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658129 | 0.88 | ITGB2 (0.77) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13662072 | 0.80 | ITGB2 (0.64) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756141 | 0.78 | ITGB2 (0.49) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18868013 | 0.76 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18867794 | 0.75 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4923073 | 0.75 | ITGB2 (0.82) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL879361 | 0.74 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16307478 | 0.74 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL17991454 | 0.74 | ITGAL (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL13894420 | 0.74 | ITGB2 (0.76) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.